Investigating genetic factors in heart disease caused by MYH7 variants
Official title: High-Throughput Studies of MYH7 Variant Cardiomyocytes to Identify Pathogenic Variants and Factors Governing Variable Expressivity of Hypertrophic Cardiomyopathy
Funded at University of Washington · NIH-11032231 · Data updated 2026-11-12
This study is looking at how certain changes in a gene called MYH7 can affect people with hypertrophic cardiomyopathy (HCM), helping to explain why some patients have different symptoms and providing useful information for them and their doctors.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | December 20, 2024 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $126,306 |
| NIH project number | 1K99HL177347-01 |
| Project ID | NIH-11032231 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with hypertrophic cardiomyopathy, particularly those with identified MYH7 gene variants.
✕Less likely to help
Patients without a diagnosis of hypertrophic cardiomyopathy or those without MYH7 gene variants may not benefit from this research.
What this research studies
This research focuses on hypertrophic cardiomyopathy (HCM), a heart condition that can lead to serious complications like heart failure. It aims to identify genetic variants in the MYH7 gene that contribute to HCM and understand why symptoms vary among patients. By using advanced cell models derived from human stem cells, the researchers will explore how these genetic variants affect heart cell function and survival. The goal is to provide clearer information for patients and their doctors about the risks associated with specific genetic changes.
Why it matters
Potential benefit: If successful, this research could lead to better risk assessment and personalized treatment options for patients with MYH7-related hypertrophic cardiomyopathy.
How similar studies have gone: Previous research has shown promise in using stem cell models to study genetic heart conditions, indicating that this approach could yield valuable insights.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Friedman, Clayton E — University of Washington
- Study coordinator: Friedman, Clayton E
Related research
Other NIH-funded projects on the same topics.
-
SGLT inhibitors for non-obstructive hypertrophic cardiomyopathy
A testing of a diabetes drug class (SGLT2 inhibitors) to help people with non-obstructive hypertrophic cardiomyopathy feel better and reduce heart-related problems.
-
Using big biobanks to understand rare gene changes in hypertrophic cardiomyopathy
A large study will look at genetic data and health information from many people to better understand how rare gene changes influence hypertrophic cardiomyopathy and its risks.
-
Understanding heart disease in hypertrophic cardiomyopathy through heart tissue and blood analysis
Researchers are studying people with hypertrophic cardiomyopathy to see how genes and signaling in heart tissue and blood relate to disease progression and risk of serious heart problems.
-
Myosin binding protein C variants and heart disease
A doctor-scientist at the University of Michigan is studying how certain genetic changes in a heart protein (MYBPC3) cause hypertrophic cardiomyopathy and whether fixing the protein or its interactions could help people with this condition.
-
MEK inhibitor for severe infantile heart failure in Noonan and related RASopathies
A 12-month, multi-site trial tests whether the medicine trametinib can help infants with life-threatening heart failure due to Noonan syndrome and related genetic conditions.
-
MEK inhibitor shows promise for serious infant heart disease in Noonan/RASopathies
A multi-site study tests whether the drug trametinib can help infants with severe heart muscle thickening caused by Noonan syndrome and related RASopathies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.